Results 221 to 230 of about 26,004 (264)

Wöchentliche Gabe von nab-Paclitaxel besonders vorteilhaft [PDF]

best practice onkologie, 2011
openaire   +1 more source

Synergistic efficacy and safety of PD-1/PD-L1 inhibitors combined with nab-paclitaxel and platinum chemotherapy in NSCLC: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Front Oncol
Shen Y.
europepmc   +1 more source

Cost-Effectiveness Analysis of Serplulimab Combined with Nab-Paclitaxel Plus Carboplatin Compared to Nab-Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer in China. [PDF]

Risk Manag Healthc Policy
Yao H, Xu K, Yu M, Wang X, Lu Y, Li X, Wu H.   +6 more
europepmc   +1 more source

Comments on the SERAPHINA study assessing the utilization, efficacy, safety, and quality of life of nab-paclitaxel in patients with advanced HER2-negative breast cancer. [PDF]

J Cancer Res Clin Oncol
Altundag K.
europepmc   +1 more source

Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. [PDF]

NPJ Precis Oncol
Bhatia R, Khan I, Li X, Gautam S, Seshacharyulu P, Alsafwani ZW, Bhyravbhatla N, Ponnusamy MP, Jain M, Malafa M, Bindu S, Gulzar A, Nair H, Batra SK, Kumar S.   +14 more
europepmc   +1 more source

The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study. [PDF]

Front Immunol
Ouyang Z, Zhang L, Wang F, Chen M, Cheng B, Yang F, Lai W, Gao J, Wang S, Tong G.   +9 more
europepmc   +1 more source

Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. [PDF]

Sci Rep
Sezgin Y, Karhan O, Aldemir MN, Ürün M, Erçek BM, Urakcı Z, Arvas H, Tunç S, Erdem M, Yerlikaya H, İleri S, Aydın İ, Bicer A, Kömüroğlu AU, Majidova N, Gökçek S, Demir H, Yıldız S, Akbaş S, Özen E, Kahya BU, Sali M, Anık H, Aykut T, Araz M, Alkan A, Özçelik M, Sakin A, Aykan MB, Mehtıyev M, Demir B, Başer MN, Sönmez M, Gültürk İ, Avcı N, Urvay S, Arıcı MÖ, Kalender ME, Yıldırım M, Solmaz AA, Gürbüz M, Ergün Y.   +41 more
europepmc   +1 more source

Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma. [PDF]

Sci Rep
Yamada D, Kobayashi S, Takahashi H, Iwagami Y, Akita H, Asukai K, Shimizu J, Yamada T, Tanemura M, Yokoyama S, Tsujie M, Asaoka T, Takeda Y, Morimoto O, Tomokuni A, Doki Y, Eguchi H.   +16 more
europepmc   +1 more source

S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure. [PDF]

Ther Adv Med Oncol
Tang H, Li Z, You T, Ying J, Yuan M, Cheng Y, Wang Y, Wu H, Bai C.   +8 more
europepmc   +1 more source

Real-World Evidence of the Efficacy and Safety of Second-Line Therapy After Gemcitabine and Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer. [PDF]

Cancers (Basel)
Adamczuk-Nurzyńska A, Nurzyński P, Brzozowska M, Jewczak M, Śliwczyński A.   +4 more
europepmc   +1 more source